Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Clear Creek Bio Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner in 1 distinct art unit, indicating a very concentrated point of engagement for the company's current patent efforts. This focused presence in the biotech sector suggests a specific technical objective or a limited volume of active prosecution at the present time.
The busiest examiner for this portfolio is SHOWALTER, ALEXANDER KEITH, who is assigned 1 pending office action. Because the busiest examiner pending count of 1 is equal to the total number of pending office actions, the company's immediate prosecution outcomes are entirely dependent on the review of this one individual. This concentration eliminates the possibility of using internal comparisons between different examiners to refine prosecution tactics for this specific portfolio.
Practitioners should focus on the specific preferences and history of SHOWALTER, ALEXANDER KEITH, as this examiner represents the sole gateway for the company's pending matter. The alignment of 1 distinct art unit with 1 distinct examiner means that the company's strategy in Biotechnology & Pharmaceuticals is currently operating through a single, narrow channel. Success in this 1 pending office action is essential for maintaining the portfolio's momentum.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOWALTER, ALEXANDER KEITH | 1 | 55.4% | +27.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18823050 | STABLE POLYMORPHIC COMPOSITIONS OF BREQUINAR SODIUM AND METHODS OF USE AND MANUFACTURE THEREOF | SHOWALTER, ALEXANDER KEITH | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18823050 | STABLE POLYMORPHIC COMPOSITIONS OF BREQUINAR SODIUM AND METHODS OF USE AND MANUFACTURE THEREOF | SHOWALTER, ALEXANDER KEITH | 1629 | §103§112DP | Non-Final OA | — | Pending | Sep 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialClear Creek Bio Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alexander Keith Showalter has the most, with 1 of Clear Creek Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
